Cargando…

MR imaging of hepatocellular carcinoma: prospective intraindividual head-to-head comparison of the contrast agents gadoxetic acid and gadoteric acid

The routine use of dynamic-contrast-enhanced MRI (DCE-MRI) of the liver using hepatocyte-specific contrast agent (HSCA) as the standard of care for the study of focal liver lesions is not widely accepted and opponents invoke the risk of a loss in near 100% specificity of extracellular contrast agent...

Descripción completa

Detalles Bibliográficos
Autores principales: Collettini, Federico, Elkilany, Aboelyazid, Seta, Marta Della, Steffen, Ingo G., Collettini, Jasmin Maya, Penzkofer, Tobias, Schmelzle, Moritz, Denecke, Timm
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9633770/
https://www.ncbi.nlm.nih.gov/pubmed/36329107
http://dx.doi.org/10.1038/s41598-022-23397-1
_version_ 1784824312439504896
author Collettini, Federico
Elkilany, Aboelyazid
Seta, Marta Della
Steffen, Ingo G.
Collettini, Jasmin Maya
Penzkofer, Tobias
Schmelzle, Moritz
Denecke, Timm
author_facet Collettini, Federico
Elkilany, Aboelyazid
Seta, Marta Della
Steffen, Ingo G.
Collettini, Jasmin Maya
Penzkofer, Tobias
Schmelzle, Moritz
Denecke, Timm
author_sort Collettini, Federico
collection PubMed
description The routine use of dynamic-contrast-enhanced MRI (DCE-MRI) of the liver using hepatocyte-specific contrast agent (HSCA) as the standard of care for the study of focal liver lesions is not widely accepted and opponents invoke the risk of a loss in near 100% specificity of extracellular contrast agents (ECA) and the need for prospective head-to-head comparative studies evaluating the diagnostic performance of both contrast agents. The Purpose of this prospective intraindividual study was to conduct a quantitative and qualitative head-to-head comparison of DCE-MRI using HSCA and ECA in patients with liver cirrhosis and HCC. Twenty-three patients with liver cirrhosis and proven HCC underwent two 3 T-MR examinations, one with ECA (gadoteric acid) and the other with HSCA (gadoxetic acid). Signal-to-noise ratio (SNR), contrast-to-noise ratio (CNR), wash-in, wash-out, image quality, artifacts, lesion conspicuity, and major imaging features of LI-RADS v2018 were evaluated. Wash-in and wash-out were significantly stronger with ECA compared to HSCA (P < 0.001 and 0.006, respectively). During the late arterial phase (LAP), CNR was significantly lower with ECA (P = 0.005), while SNR did not differ significantly (P = 0.39). In qualitative analysis, ECA produced a better overall image quality during the portal venous phase (PVP) and delayed phase (DP) compared to HSCA (P = 0.041 and 0.008), showed less artifacts in the LAP and PVP (P = 0.003 and 0.034) and a higher lesion conspicuity in the LAP and PVP (P = 0.004 and 0.037). There was no significant difference in overall image quality during the LAP (P = 1), in artifacts and lesion conspicuity during the DP (P = 0.078 and 0.073) or in the frequency of the three major LI-RADS v2018 imaging features. In conclusion, ECA provides superior contrast of HCC—especially hypervascular HCC lesions—in DCE-MR in terms of better perceptibility of early enhancement and a stronger washout.
format Online
Article
Text
id pubmed-9633770
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-96337702022-11-05 MR imaging of hepatocellular carcinoma: prospective intraindividual head-to-head comparison of the contrast agents gadoxetic acid and gadoteric acid Collettini, Federico Elkilany, Aboelyazid Seta, Marta Della Steffen, Ingo G. Collettini, Jasmin Maya Penzkofer, Tobias Schmelzle, Moritz Denecke, Timm Sci Rep Article The routine use of dynamic-contrast-enhanced MRI (DCE-MRI) of the liver using hepatocyte-specific contrast agent (HSCA) as the standard of care for the study of focal liver lesions is not widely accepted and opponents invoke the risk of a loss in near 100% specificity of extracellular contrast agents (ECA) and the need for prospective head-to-head comparative studies evaluating the diagnostic performance of both contrast agents. The Purpose of this prospective intraindividual study was to conduct a quantitative and qualitative head-to-head comparison of DCE-MRI using HSCA and ECA in patients with liver cirrhosis and HCC. Twenty-three patients with liver cirrhosis and proven HCC underwent two 3 T-MR examinations, one with ECA (gadoteric acid) and the other with HSCA (gadoxetic acid). Signal-to-noise ratio (SNR), contrast-to-noise ratio (CNR), wash-in, wash-out, image quality, artifacts, lesion conspicuity, and major imaging features of LI-RADS v2018 were evaluated. Wash-in and wash-out were significantly stronger with ECA compared to HSCA (P < 0.001 and 0.006, respectively). During the late arterial phase (LAP), CNR was significantly lower with ECA (P = 0.005), while SNR did not differ significantly (P = 0.39). In qualitative analysis, ECA produced a better overall image quality during the portal venous phase (PVP) and delayed phase (DP) compared to HSCA (P = 0.041 and 0.008), showed less artifacts in the LAP and PVP (P = 0.003 and 0.034) and a higher lesion conspicuity in the LAP and PVP (P = 0.004 and 0.037). There was no significant difference in overall image quality during the LAP (P = 1), in artifacts and lesion conspicuity during the DP (P = 0.078 and 0.073) or in the frequency of the three major LI-RADS v2018 imaging features. In conclusion, ECA provides superior contrast of HCC—especially hypervascular HCC lesions—in DCE-MR in terms of better perceptibility of early enhancement and a stronger washout. Nature Publishing Group UK 2022-11-03 /pmc/articles/PMC9633770/ /pubmed/36329107 http://dx.doi.org/10.1038/s41598-022-23397-1 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Collettini, Federico
Elkilany, Aboelyazid
Seta, Marta Della
Steffen, Ingo G.
Collettini, Jasmin Maya
Penzkofer, Tobias
Schmelzle, Moritz
Denecke, Timm
MR imaging of hepatocellular carcinoma: prospective intraindividual head-to-head comparison of the contrast agents gadoxetic acid and gadoteric acid
title MR imaging of hepatocellular carcinoma: prospective intraindividual head-to-head comparison of the contrast agents gadoxetic acid and gadoteric acid
title_full MR imaging of hepatocellular carcinoma: prospective intraindividual head-to-head comparison of the contrast agents gadoxetic acid and gadoteric acid
title_fullStr MR imaging of hepatocellular carcinoma: prospective intraindividual head-to-head comparison of the contrast agents gadoxetic acid and gadoteric acid
title_full_unstemmed MR imaging of hepatocellular carcinoma: prospective intraindividual head-to-head comparison of the contrast agents gadoxetic acid and gadoteric acid
title_short MR imaging of hepatocellular carcinoma: prospective intraindividual head-to-head comparison of the contrast agents gadoxetic acid and gadoteric acid
title_sort mr imaging of hepatocellular carcinoma: prospective intraindividual head-to-head comparison of the contrast agents gadoxetic acid and gadoteric acid
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9633770/
https://www.ncbi.nlm.nih.gov/pubmed/36329107
http://dx.doi.org/10.1038/s41598-022-23397-1
work_keys_str_mv AT collettinifederico mrimagingofhepatocellularcarcinomaprospectiveintraindividualheadtoheadcomparisonofthecontrastagentsgadoxeticacidandgadotericacid
AT elkilanyaboelyazid mrimagingofhepatocellularcarcinomaprospectiveintraindividualheadtoheadcomparisonofthecontrastagentsgadoxeticacidandgadotericacid
AT setamartadella mrimagingofhepatocellularcarcinomaprospectiveintraindividualheadtoheadcomparisonofthecontrastagentsgadoxeticacidandgadotericacid
AT steffeningog mrimagingofhepatocellularcarcinomaprospectiveintraindividualheadtoheadcomparisonofthecontrastagentsgadoxeticacidandgadotericacid
AT collettinijasminmaya mrimagingofhepatocellularcarcinomaprospectiveintraindividualheadtoheadcomparisonofthecontrastagentsgadoxeticacidandgadotericacid
AT penzkofertobias mrimagingofhepatocellularcarcinomaprospectiveintraindividualheadtoheadcomparisonofthecontrastagentsgadoxeticacidandgadotericacid
AT schmelzlemoritz mrimagingofhepatocellularcarcinomaprospectiveintraindividualheadtoheadcomparisonofthecontrastagentsgadoxeticacidandgadotericacid
AT denecketimm mrimagingofhepatocellularcarcinomaprospectiveintraindividualheadtoheadcomparisonofthecontrastagentsgadoxeticacidandgadotericacid